Protagonist Therapeutics (PTGX) Amortization of Deferred Charges (2019 - 2021)

Protagonist Therapeutics has reported Amortization of Deferred Charges for 4 years, with the latest figure at $418000.0 in Q4 2024.

• Quarterly Amortization of Deferred Charges fell 28.42% year-over-year to $418000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $2.1 million (down 11.39% YoY) and the FY2024 annual result came in at $2.1 million, down 11.39% from the prior year.
• Amortization of Deferred Charges was little changed at $418000.0 in Q4 2024 per PTGX's latest filing, from $416000.0 in the prior quarter.
• Over five years, Amortization of Deferred Charges peaked at $651000.0 in Q2 2024 and troughed at $416000.0 in Q3 2024.
• A 4-year average of $543812.5 and a median of $584000.0 in 2021 frame the typical range for Amortization of Deferred Charges.
• The sharpest annual moves came in 2022 and 2024: Amortization of Deferred Charges surged 31.83% in 2022, then retreated 28.64% in 2024.
• Over 4 years, Amortization of Deferred Charges stood at $584000.0 in 2021, then changed by 0.0% to $584000.0 in 2022, then changed by 0.0% to $584000.0 in 2023, then dropped by 28.42% to $418000.0 in 2024.
• According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $418000.0, $416000.0, and $651000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.